Australia's most trusted
source of pharma news
Monday, 29 June 2026
Posted 29 June 2026 PM
Two long-awaited Novo Nordisk drugs, Sogroya and Tresiba Penfill, will join the PBS for the first time next month.
As of 1 July, Sogroya will be listed on the scheme for children aged two years and above with short stature due to growth hormone deficiency (GHD), an indication recommended by the PBAC three years ago.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.